Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction

A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Assess The Duration Of Action, Safety And Toleration Of Differing Doses and Combinations Of Immediate and Modified Release Formulations Of UK-369,003 and Cialis Compared To Placebo In Adult Male Subjects With Erectile Dysfunction

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00174486

Enrollment

300

Registered

2005-09-15

Start date

2005-02-28

Completion date

2005-06-30

Last updated

2006-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impotence

Brief summary

Assessment of duration of action, safety & toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks.

Interventions

DRUGUK0369,003

DRUGCialis (Tadalafil)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Erectile Dysfunction

Exclusion criteria

* Alpha blockers and Nitrates of any preparation

Design outcomes

Primary

Measure	Time frame
Assessment of duration of action, safety & toleration of the investigational drug and Cialis	—

Secondary

Measure	Time frame
Assess safety & toleration over 4 week treatment period	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026